PMID: 2512171Nov 1, 1989Paper

Primary medical therapy for operable breast cancer

European Journal of Cancer & Clinical Oncology
J L MansiJ A McKinna

Abstract

Fifty-seven patients with large but potentially operable primary breast cancer were treated with primary medical therapy rather than initial mastectomy, using chemotherapy (15) or endocrine therapy (42) with the tumour remaining in situ. Of patients treated with chemotherapy, one (7%) achieved a complete remission, and eight (53%) a partial response (overall response rate 60%). Only one patient had progressive disease while on chemotherapy. Of patients who received endocrine therapy, one (2%) achieved a complete response, and 19 (45%) a partial response (overall response rate 47%). Two patients progressed on endocrine therapy. Only 10 patients have so far had a subsequent mastectomy (18%), and 17 (30%) have had radiotherapy and/or conservative surgery. The rest are still on medical therapy. With a median follow-up of 19 months (range 6-42 months) only two patients have had a local recurrence after being disease-free and none have developed uncontrollable local recurrence. Eight (14%) have developed distant metastases and four (7%) have died of metastatic disease. Primary medical therapy may offer an effective alternative to mastectomy for patients with operable breast carcinomas too large for conservative surgery and merits fur...Continue Reading

References

Jan 1, 1978·Cancer Chemotherapy and Pharmacology·M De LenaG Bonadonna
Oct 11, 1986·Lancet·A P ForrestT J Anderson
Mar 26, 1988·Lancet·P ValagussaG Bonadonna
Aug 20, 1988·BMJ : British Medical Journal·J F RobertsonR W Blamey
Jan 1, 1988·International Journal of Radiation Oncology, Biology, Physics·J Boyages, A O Langlands
Dec 1, 1987·Journal of Surgical Oncology·A KumarN N Khanna
Feb 1, 1984·Annals of Surgery·C D Haagensen, C Bodian
Mar 1, 1980·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R D RubensJ L Hayward

❮ Previous
Next ❯

Citations

Jan 1, 1994·Breast Cancer Research and Treatment·A A CollettaM Baum
Oct 2, 1998·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·I E Smith, M al-Moundhri
Dec 17, 2002·Critical Reviews in Oncology/hematology·Catherine Shannon, Ian Smith
Jan 20, 2005·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Seema SinghAnand Kumar
Mar 22, 2002·The Lancet Oncology·I E Smith, L Lipton
Apr 8, 2014·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·J L MorganL Wyld
Feb 15, 2005·Cancer Treatment Reviews·O C FreedmanM J Clemons
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R C SteinR C Coombes
Aug 16, 2006·The Breast : Official Journal of the European Society of Mastology·Rosalba TorrisiAron Goldhirsch
Feb 18, 2004·The Breast : Official Journal of the European Society of Mastology·K L Cheung, J F Robertson
Apr 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T R Jeffry EvansJanine L Mansi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.